NEVVI Medicare utilization intelligence
or

← back

Provider profile

LAFARGUE, CHRISTOPHER M.D.

Obstetrics & Gynecology · NPI 1306286166 · FORT WORTH, TX

1
Groups
43
Codes · 2024
38,378
Disclosed services

LAFARGUE, CHRISTOPHER is a Obstetrics & Gynecology in FORT WORTH, TX, a member of 1 medical group, who billed 43 distinct codes to Medicare Part B in 2024.

Groups: TEXAS ONCOLOGY PA (DALLAS, TX)

Year: 2024 · 2023 · 2022 🔒 · 2021 🔒

Provider overview · all codes · CY2024

38,378
disclosed services
43
codes billed to Medicare Part B
Prior year · CY2023 36,040 disclosed services

This provider's disclosed Medicare payments across all codes were in CY2024.

Dollars, place-of-service mix, business mix and national standing are part of the market analytics platform — built, not launched yet. Notify me at launch →

All figures are disclosed (CMS suppresses fewer-than-11-beneficiary rows) Medicare Part B fee-for-service — a subset, never complete totals; volumes are personal to this NPI, not attributed to any group. Standing is a billed-volume position among specialty peers with disclosed billing (national percentile; a provider's true standing can only be higher, never lower), not a statement about care. See Methods & Sources.

Procedures billed to Medicare Part B (2024)

Medicare Part B FFS · CY2024 · as published by CMS
This provider's Medicare volumes — services, beneficiary-episodes, and charges — are part of the market analytics platform — built, not launched yet. Notify me at launch →
CodeDescription Services Beneficiary-episodes Avg charge Avg Medicare payment
J1453 Injection, fosaprepitant, 1 mg
J9267 Injection, paclitaxel, 1 mg
J9025 Injection, azacitidine, 1 mg
J9271 Injection, pembrolizumab, 1 mg
J0881 Injection, darbepoetin alfa, 1 microgram (non-esrd use)
J1100 Injection, dexamethasone sodium phosphate, 1 mg
J1626 Injection, granisetron hydrochloride, 100 mcg
J2469 Injection, palonosetron hcl, 25 mcg
36415 Insertion of needle into vein for collection of blood sample
J9196 Injection, gemcitabine hydrochloride (accord), not therapeutically equivalent to j9201, 200 mg
96367 Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less
80053 Blood test, comprehensive group of blood chemicals
96413 Administration of chemotherapy into vein, 1 hour or less
99214 Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more
85025 Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count
J9045 Injection, carboplatin, 50 mg
86304 Immunologic analysis for detection of tumor antigen, quantitative; ca 125
96375 Injection of additional new drug or substance into vein
G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's
J3489 Injection, zoledronic acid, 1 mg
96401 Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle
J1200 Injection, diphenhydramine hcl, up to 50 mg
96415 Administration of chemotherapy into vein, each additional hour
96417 Administration of additional new drug or substance into vein, 1 hour or less
96365 Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less
99215 Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more
99213 Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more
96372 Injection of drug or substance under skin or into muscle
81001 Manual urinalysis test with examination using microscope, automated
J3490 Unclassified drugs
99204 New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more
J7030 Infusion, normal saline solution , 1000 cc
96361 Infusion into a vein for hydration, each additional hour
J7040 Infusion, normal saline solution, sterile (500 ml = 1 unit)
78815 Nuclear medicine study from skull base to mid-thigh with ct scan
A9552 Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries
96402 Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle
G0498 Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l
96411 Administration of additional new drug or substance into vein using push technique
96368 Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion
86301 Immunologic analysis for detection of tumor antigen, quantitative; ca 19-9
82378 Carcinoembryonic antigen (cea) protein level
99205 New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more

These are this provider's own Medicare Part B fee-for-service volumes (CMS public data). CMS suppresses rows with fewer than 11 beneficiaries, so low-volume codes may be missing entirely — absence is not zero. Beneficiary-episodes count CMS's per-setting beneficiary figures, not unique patients. Average charge and average Medicare payment are weighted by service volume across office and facility settings. Volumes on this page are personal to the NPI and are not attributed to any physician group. See Methods & Sources.